Reduce CL 15-20% to Underweight on margin compression and stretched valuation despite dividend defensives
Underweight rating reflects that operating margin deterioration (Q2: -5.9% op income with +4.9% revenue, -210bps margin compression), stretched normalized P/E of ~27.5x for a 2-3% organic grower, and negative technical momentum (three failed resistance tests at $94.32-$95.46, MACD histogram at +0.09) outweigh the structural defensives (fortress balance sheet, Hill's pet nutrition moat, 2.27% dividend yield). The 15-20% trim calibrated below the 25-33% proposal honors the thin-volume concern (2.7M August 10 volume) and preserves optionality ahead of the Q3 binary catalyst while avoiding the DUK lesson pitfall of passive Hold in a bearish-aligned setup.
| Position | Action |
|---|---|
| Current overweight position in CL | Trim 15-20% of existing position to establish modest underweight |
CL is a quality compounder with re-accelerating revenue growth, demonstrable pricing power, and exemplary capital discipline that deserves a BUY rating with strategic entry points, not a passive HOLD.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | 92.49 | bullish |
| 50 SMA | 90.75 | bullish |
| 200 SMA | 85.55 | bullish |
| RSI | 54.84 | neutral |
| MACD | 0.53 | bullish |
| MACD Signal | 0.44 | bullish |
| MACD Histogram | 0.09 | neutral |
| Bollinger Middle | 91.93 | neutral |
| Bollinger Upper | 94.32 | neutral |
| Bollinger Lower | 89.54 | neutral |
| ATR | 2.36 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Then: Re-establish core position
↩ rebuts: “Bear's focus on operating margin compression as evidence of pricing weakness”
EV: +4–5% (to $94.32 → $95.46 → $96.97) · concedes: MACD histogram is small at +0.09; RSI at 54.84 is neutral; Volume is thin on recent sessions; The technicals are NOT screaming 'buy now' — exactly why strategic entry points matter; Price trades near 52-week high at $93.15; Director John Cahill sold 4,170 shares for $389K (though contextualized as routine 2019-vintage option exercise with $6.02M retained)
CL's price has run ahead of deteriorating fundamentals — operating income fell 5.9% YoY despite 4.9% revenue growth, margins compressed 210bps, volumes are flat, momentum is diverging bearish, and a normalized P/E of ~27.5x makes current levels unattractive with asymmetric downside risk to the $85.55 200 SMA.
EV: -$85.55 (8% downside to 200 SMA) · concedes: Single insider sale from option exercise is typically noise rather than signal; The company's 2.27% dividend yield provides some income support; Price is technically above both 50 SMA ($90.75) and 200 SMA ($85.55); A daily close below $89.50 (lower Bollinger Band) would be the actual breakdown trigger, and if the stock subsequently holds $85.55 and margin compression reverses, a HOLD stance becomes appropriate
→ vs conservative: The 'fortress balance sheet Dividend Aristocrat' thesis is a yield trap — if multiple compresses from 27.5x to 22x, investors face 20% capital drawdown that takes over a decade of dividends to recover
→ vs conservative: Treating operating leverage working in reverse as 'investment behind brands' ignores structural margin compression from private-label competition and SG&A bloat
→ vs conservative: Dividend reliability does not protect against multiple compression — CL paid and grew dividends while dropping from $89 to $67 in 2022-2023
→ vs neutral: HOLD recommendation is 'decision paralysis dressed up as prudence' — the asymmetry is already decisively negative at current levels
→ vs neutral: Waiting for 'confirmation' of organic growth re-acceleration means buying into deteriorating fundamentals with 210bps margin compression and flat volumes
→ vs neutral: Standaside approach misses opportunity to trim into weakness and redeploy capital to higher-reward setups at $85-87
Support: 94.32 · 95.46 · 93.5 · 93.15 · 92.49 · 90.75 · 89.54 · 85.55 · 84.39 | Resistance: 94.32 · 95.46 · 93.5 · 93.15 · 92.49 · 90.75 · 89.54 · 85.55 · 84.39
CL is structurally bullish with price (93.15) above both the 50 SMA (90.75) and 200 SMA (85.55), confirming the uptrend that began in late October 2025. Short-term momentum is mildly bullish—price above the 10 EMA (92.49) and MACD (0.53) above signal (0.44)—but the MACD histogram of 0.09 and RSI at 54.84 indicate cooling momentum rather than acceleration. The stock is pressing into a known resistance zone ($94.32–$95.46, defined by the Bollinger Upper Band and July highs at $94.49 and $95.46) on notably low volume of 2.7M versus the 13–17M surges seen during the January 2026 breakout. Key support sits at the 50 SMA ($90.75) and Bollinger lower band ($89.54), with deeper support at the 200 SMA ($85.55). Preferred bias is neutral-to-mildly bullish; the report recommends HOLD as the cleanest entry setups require either a pullback to the 50 SMA ($90.75–$91.50) with stop below $89.50, or a breakout above $94.50 on volume above 5–6M. A stop of 1.0–1.5 ATR (~$2.50–$3.54) is recommended for any long positions.
Market Cap
$74.26B
P/E (TTM)
36.67x
Forward P/E
22.72x
PEG Ratio
1.80
Price/Book
314.70x
Dividend Yield
2.27%
Beta
0.327
52-Week High
$99.33
52-Week Low
$74.55
50-Day MA
$91.07
200-Day MA
$86.39
Revenue (TTM)
$21.05B
Gross Profit (TTM)
$12.72B
EBITDA (TTM)
$4.98B
Net Income (TTM)
$2.04B
Operating Margin (TTM)
20.97%
Profit Margin (TTM)
9.68%
Return on Equity (TTM)
267.37%
Return on Assets (TTM)
15.84%
Total Assets
$16.79B
Total Debt
$7.86B
Cash & Equivalents
$1.37B
Net Debt
$6.49B
Net Debt/EBITDA
~1.3x
Debt/Equity
1,388%
Current Ratio
1.026
Stockholders' Equity
$236M
Treasury Stock
$28.93B
Goodwill + Intangibles
$4.60B
Operating Cash Flow (TTM)
~$4.86B
Free Cash Flow (TTM)
$3.46B
CapEx (TTM)
~$0.60B
Dividends Paid (TTM)
~$1.82B
Share Buybacks (TTM)
~$1.23B
Revenue Growth (Q2 YoY)
+4.9%
Gross Margin (Q2 2026)
61.5%
Operating Margin (Q2 2026)
19.0%
Debt Reduction (4Q)
-$1.21B
Tax Rate (Q2 2026)
~24.3%
Interest Expense (Q2 2026)
$62M
International Revenue
75%+
Strengths
Concerns
Colgate-Palmolive is a best-in-class defensive mega-cap consumer staples franchise with iconic global brands, generating $21.05B in TTM revenue and $3.46B in free cash flow. The company shows encouraging Q2 2026 trends with revenue acceleration to 4.9% YoY and gross margin expansion to 61.5% (up 140bp), though operating margins have compressed to 19.0% from 21.1% YoY due to elevated SG&A costs. The TTM P/E of 36.67x is inflated by a one-time $866M impairment charge in Q4 2025, with forward P/E of 22.72x providing a more representative valuation. The stock trades near 52-week highs at ~84% of the 52-week range, offering limited margin of safety for new investors but presenting a strong defensive holding with consistent capital returns and low beta (0.33).
Macro: Oil prices re-accelerated after failed diplomatic resolution to Middle East conflict dashed hopes for Strait of Hormuz reopening; Gulf exports ~40% below pre-war. U.S. equities slipped on inflation fears (Aug 10). Fed is on hold (86% probability of no cuts in 2026); recession odds at 8% (soft landing base case). Japan 32%, UK 18%. China July PPI slowed more than expected, providing deflationary impulse. Markets positioned ahead of CPI/PCE prints as binding macro variables.